Exendin-4 Reduces Ischemic Brain Injury in Normal and Aged Type 2 Diabetic Mice and Promotes Microglial M2 Polarization
Open accessThe DOI matches its Crossref record; 40 of the 41 references it cites were found in a registry or an index.
Abstract
Exendin-4 is a glucagon-like receptor 1 agonist clinically used against type 2 diabetes that has also shown neuroprotective effects in experimental stroke models. However, while the neuroprotective efficacy of Exendin-4 has been thoroughly investigated if the pharmacological treatment starts before stroke, the therapeutic potential of the Exendin-4 if the treatment starts acutely after stroke has not been clearly determined. Further, a comparison of the neuroprotective efficacy in normal and aged diabetic mice has not been performed. Finally, the cellular mechanisms behind the efficacy of Exendin-4 have been only partially studied. The main objective of this study was to determine the neuroprotective efficacy of Exendin-4 in normal and aged type 2 diabetic mice if the treatment started after stroke in a clinically relevant setting. Furthermore we characterized the Exendin-4 effects on stroke-induced neuroinflammation. Two-month-old healthy and 14-month-old type 2 diabetic/obese mice were subjected to middle cerebral artery occlusion. 5 or 50 µg/kg Exendin-4 was administered intraperitoneally at 1.5, 3 or 4.5 hours thereafter. The treatment was continued (0.2 µg/kg/day) for 1 week. The neuroprotective efficacy was assessed by stroke volume measurement and stereological counting of NeuN-positive neurons. Neuroinflammation was determined by gene expression analysis of M1/M2 microglia subtypes and pro-inflammatory cytokines. We show neuroprotective efficacy of 50 µg/kg Exendin-4 at 1.5 and 3 hours after stroke in both young healthy and aged diabetic/obese mice. The 5 µg/kg dose was neuroprotective at 1.5 hour only. Proinflammatory markers and M1 phenotype were not impacted by Exendin-4 treatment while M2 markers were significantly up regulated. Our results support the use of Exendin-4 to reduce stroke-damage in the prehospital/early hospitalization setting irrespectively of age/diabetes. The results indicate the polarization of microglia/macrophages towards the M2 reparative phenotype as a potential mechanism of neuroprotection.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Hence, GLP-1RAs can attenuate neuroinflammation through microglial M2 polarization [76].”
From Protection against stroke with glucagon-like peptide-1 receptor agonists: a comprehensive review of potential mechanisms (2022) · cites this paper as [76]
In the citing paper
“Moreover, in both young and aged diabetic mice subjected to MCAO, exendin-4 treatment was shown to significantly polarize microglia/macrophages towards an anti-inflammatory M2 phenotype in the injured hemisphere compared to the non-injured hemisphere [76].”
From Protection against stroke with glucagon-like peptide-1 receptor agonists: a comprehensive review of potential mechanisms (2022) · cites this paper as [76]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tissue Plasminogen Activator for Acute Ischemic Stroke
(1995) · New England Journal of Medicine · doi:10.1056/nejm199512143332401 · Cited by 11,654
Macrophage plasticity and polarization: in vivo veritas
Sica, A., & Mantovani, A. (2012) · Journal of Clinical Investigation · doi:10.1172/jci59643 · Cited by 6,335 · cited 1×
“the classical proinflammatory M1 phenotype and the wound-healing reparative M2 phenotype respectively [24].”
Pathobiology of ischaemic stroke: an integrated view
Dirnagl, U., Iadecola, C., & Moskowitz, M. A. (1999) · Trends in Neurosciences · doi:10.1016/s0166-2236(99)01401-0 · Cited by 3,943 · cited 1×
“Inflammation is a key mediator in brain damage after stroke [20–23].”
Drucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896 · cited 3×
“In addition to direct neuroprotective effects also supported by GLP-1R expression in neurons [38], the regulation of inflammation has been suggested as one potential mechanism since Ex-4 decreases the number of microglia after stroke [16,18,19].”
InfluentialIschemia and reperfusion—from mechanism to translation
Eltzschig, H. K., & Eckle, T. (2011) · Nature Medicine · doi:10.1038/nm.2507 · Cited by 3,382 · cited 1×
“Inflammation is a key mediator in brain damage after stroke [20–23].”
Kigerl, K. A., Gensel, J. C., Ankeny, D. P., Alexander, J. K., Donnelly, D. J., & Popovich, P. G. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.3257-09.2009 · Cited by 2,130 · cited 2×
“Similar to that shown after both spinal cord injury [40] and focal cerebral ischemia [25], we found an increased expression of both M1 and M2 markers 3 days after MCAO.”
Hu, X., Li, P., Guo, Y., Wang, H., Leak, R. K., Chen, S., Gao, Y., & Chen, J. (2012) · Stroke · doi:10.1161/strokeaha.112.659656 · Cited by 1,535 · cited 2×
“Similar to that shown after both spinal cord injury [40] and focal cerebral ischemia [25], we found an increased expression of both M1 and M2 markers 3 days after MCAO.”
Inflammatory mechanisms in ischemic stroke: role of inflammatory cells
Jin, R., Yang, G., & Li, G. (2010) · Journal of Leukocyte Biology · doi:10.1189/jlb.1109766 · Cited by 1,521 · cited 1×
“Inflammation is a key mediator in brain damage after stroke [20–23].”
Update of the Stroke Therapy Academic Industry Roundtable Preclinical Recommendations
Fisher, M., Feuerstein, G., Howells, D. W., Hurn, P. D., Kent, T. A., Savitz, S. I., & Lo, E. H. (2009) · Stroke · doi:10.1161/strokeaha.108.541128 · Cited by 1,352 · cited 1×
“Overall, the differential stroke outcome between normal and T2D/obese mice underscores the importance to study stroke and potential therapies by using stroke models with comorbidities as recommended by the STAIR group [36].”
Gladstone, D. J., Black, S. E., & Hakim, A. M. (2002) · Stroke · doi:10.1161/01.str.0000025518.34157.51 · Cited by 635
Li, Y., Perry, T., Kindy, M. S., Harvey, B. K., Tweedie, D., Holloway, H. W., Powers, K., Shen, H., Egan, J. M., Sambamurti, K., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0806720106 · Cited by 589 · cited 1×
“With regard to stroke, intracerebral administration of Ex-4 before stroke resulted in neuroprotection [15].”
Reducing in-hospital delay to 20 minutes in stroke thrombolysis
Meretoja, A., Strbian, D., Mustanoja, S., Tatlisumak, T., Lindsberg, P. J., & Kaste, M. (2012) · Neurology · doi:10.1212/wnl.0b013e31825d6011 · Cited by 560
Hara, H., Huang, P. L., Panahian, N., Fishman, M. C., & Moskowitz, M. A. (1996) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1097/00004647-199607000-00010 · Cited by 411
How can we improve the pre-clinical development of drugs for stroke?
Sena, E., van der Worp, H. B., Howells, D., & Macleod, M. (2007) · Trends in Neurosciences · doi:10.1016/j.tins.2007.06.009 · Cited by 365 · cited 2×
“Because of this, several preclinically successful candidate drugs (used before/few minutes after stroke) have failed in clinical trials once administered to patients several hours after stroke [3,31,32].”
Entry of exendin-4 into brain is rapid but may be limited at high doses
Kastin, A. J., & Akerstrom, V (2003) · International Journal of Obesity · doi:10.1038/sj.ijo.0802206 · Cited by 355 · cited 1×
“Besides its anti-diabetic properties, Ex-4 has been shown to cross the blood brain barrier (BBB) [11] in dosedependent manner and preclinical work supports a neuroprotective role of Ex-4 in animal models of neurological disorders (reviewed in [12–14]).”
Li, X., Blizzard, K. K., Zeng, Z., DeVries, A. C., Hurn, P. D., & McCullough, L. D. (2004) · Experimental Neurology · doi:10.1016/j.expneurol.2004.01.004 · Cited by 303 · cited 2×
“Furthermore, at 2 weeks after stroke, even the most accurate tests at their disposal failed to recognize functional differences between untreated mice and mice treated with estrogen (well recognized neuroprotective substance) [37].”
Central effects of GLP-1: new opportunities for treatments of neurodegenerative diseases
Hölscher, C. (2014) · Journal of Endocrinology · doi:10.1530/joe-13-0221 · Cited by 288 · cited 1×
“Besides its anti-diabetic properties, Ex-4 has been shown to cross the blood brain barrier (BBB) [11] in dosedependent manner and preclinical work supports a neuroprotective role of Ex-4 in animal models of neurological disorders (reviewed in [12–14]).”
Prioritizing interventions to improve rates of thrombolysis for ischemic stroke
California Acute Stroke Pilot Registry (CASPR) Investigators (2005) · Neurology · doi:10.1212/01.wnl.0000151850.39648.51 · Cited by 274
Salcedo, I., Tweedie, D., Li, Y., & Greig, N. H. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2012.01971.x · Cited by 259 · cited 1×
“Besides its anti-diabetic properties, Ex-4 has been shown to cross the blood brain barrier (BBB) [11] in dosedependent manner and preclinical work supports a neuroprotective role of Ex-4 in animal models of neurological disorders (reviewed in [12–14]).”
Stroke patterns, etiology, and prognosis in patients with diabetes mellitus
Karapanayiotides, T., Piechowski-Jozwiak, B., van Melle, G., Bogousslavsky, J., & Devuyst, G. (2004) · Neurology · doi:10.1212/01.wnl.0000123252.55688.05 · Cited by 257
Glucagon-like peptide analogues for type 2 diabetes mellitus
Shyangdan, D. S., Royle, P., Clar, C., Sharma, P., Waugh, N., & Snaith, A. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006423.pub2 · Cited by 246
What do we know about the secretion and degradation of incretin hormones?
Deacon, C. F. (2005) · Regulatory Peptides · doi:10.1016/j.regpep.2004.06.007 · Cited by 241 · cited 1×
“However, GLP1 has a very short half-life in the peripheral blood mainly due to rapid enzymatic degradation [9].”
Lansberg, M. G., Bluhmki, E., & Thijs, V. N. (2009) · Stroke · doi:10.1161/strokeaha.109.552547 · Cited by 232 · cited 1×
“Today, tissue plasminogen activator (tPA) is the only established pharmacological treatment that restores brain reperfusion [6].”
Neuroprotection in Cerebral Ischaemia: Facts and Fancies – The Need for New Approaches
Wahlgren, N. G., & Ahmed, N. (2004) · Cerebrovascular Diseases · doi:10.1159/000074808 · Cited by 228 · cited 2×
“Because of this, several preclinically successful candidate drugs (used before/few minutes after stroke) have failed in clinical trials once administered to patients several hours after stroke [3,31,32].”
Hamilton, A., & Hölscher, C. (2009) · NeuroReport · doi:10.1097/wnr.0b013e32832fbf14 · Cited by 227
Glucagon-like peptide-1 inhibits LPS-induced IL-1β production in cultured rat astrocytes
Iwai, T., Ito, S., Tanimitsu, K., Udagawa, S., & Oka, J.-I. (2006) · Neuroscience Research · doi:10.1016/j.neures.2006.04.008 · Cited by 207 · cited 1×
“Furthermore, it has been shown that GLP-1 treatment decreases LPS-induced inflammation in astrocytes in vitro [39].”
BackgroundTeramoto, S., Miyamoto, N., Yatomi, K., Tanaka, Y., Oishi, H., Arai, H., Hattori, N., & Urabe, T. (2011) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2011.51 · Cited by 201
Novel therapeutic strategies targeting innate immune responses and early inflammation after stroke
Shichita, T., Ago, T., Kamouchi, M., Kitazono, T., Yoshimura, A., & Ooboshi, H. (2012) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2012.07941.x · Cited by 136 · cited 1×
“Inflammation is a key mediator in brain damage after stroke [20–23].”
Acute Ischemic Stroke: Time, Penumbra, and Reperfusion
Manning, N. W., Campbell, B. C. V., Oxley, T. J., & Chapot, R. (2014) · Stroke · doi:10.1161/strokeaha.113.003798 · Cited by 132
Darsalia, V., Mansouri, S., Ortsäter, H., Olverling, A., Nozadze, N., Kappe, C., Iverfeldt, K., Tracy, L. M., Grankvist, N., Sjöholm, Å., et al. (2012) · Clinical Science · doi:10.1042/cs20110374 · Cited by 130 · cited 3×
“However it is most likely related to the differences in study design between this current study and the ones previously published [16,18,19] where the Ex-4 treatment was initiated before or at the time of stroke and the effect on stroke size was dramatic.”
Self-citationGlucagon‐like peptide 1 receptor stimulation as a means of neuroprotection
Harkavyi, A., & Whitton, P. S. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2009.00486.x · Cited by 125 · cited 1×
“Besides its anti-diabetic properties, Ex-4 has been shown to cross the blood brain barrier (BBB) [11] in dosedependent manner and preclinical work supports a neuroprotective role of Ex-4 in animal models of neurological disorders (reviewed in [12–14]).”
Hyun Lee, C., Yan, B., Yoo, K., Choi, J. H., Kwon, S., Her, S., Sohn, Y., Hwang, I. K., Cho, J. H., Kim, Y., et al. (2011) · Journal of Neuroscience Research · doi:10.1002/jnr.22596 · Cited by 118 · cited 2×
“However it is most likely related to the differences in study design between this current study and the ones previously published [16,18,19] where the Ex-4 treatment was initiated before or at the time of stroke and the effect on stroke size was dramatic.”
Turner, R. C., Dodson, S. C., Rosen, C. L., & Huber, J. D. (2013) · Journal of Neurosurgery · doi:10.3171/2012.11.jns12408 · Cited by 86 · cited 1×
“Neuroprotective strategies aimed at decreasing brain damage after stroke have failed to be translated into the clinical setting along the past decades [3] [4,5].”
Stridh, L., Mottahedin, A., Johansson, M. E., Valdez, R. C., Northington, F., Wang, X., & Mallard, C. (2013) · Journal of Neuroscience · doi:10.1523/jneurosci.0673-13.2013 · Cited by 82 · cited 1×
“Further, we have previously shown that increased vulnerability after brain injury was associated with a decrease in reparative M2 microglia [41].”
Self-citationRepeated administration of exendin-4 reduces focal cerebral ischemia-induced infarction in rats
Briyal, S., Gulati, K., & Gulati, A. (2011) · Brain Research · doi:10.1016/j.brainres.2011.10.026 · Cited by 71 · cited 1×
“However, in these studies the neuroprotective efficacy was achieved either by using strategies based on pretreatment [16,17], or by using experimental paradigms difficult to be translated to the clinical reality, e.”
Age-related changes in brain support cells: Implications for stroke severity
Sohrabji, F., Bake, S., & Lewis, D. K. (2013) · Neurochemistry International · doi:10.1016/j.neuint.2013.06.013 · Cited by 70 · cited 1×
“in [1]).”
Neuroprotection Does Not Work!
Röther, J. (2008) · Stroke · doi:10.1161/strokeaha.107.494799 · Cited by 67
Reducing the risk of stroke in type 2 diabetes: pathophysiological and therapeutic perspectives
Sander, D., & Kearney, M. T. (2009) · Journal of Neurology · doi:10.1007/s00415-009-5143-1 · Cited by 54 · cited 1×
“doubles the risk of stroke recurrence and increases mortality (reviewed in [2]).”
The protective effect of risk factors against stroke severity
Steiner, I., Gotkine, M., & Wirguin, I. (2008) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2007.10.021 · Cited by 6 · cited 1×
“It is known, that diabetes can induce alterations in the cerebral blood flow on microvascular level [34,35] and such alterations could be behind the differential response to MCAO between adult/healthy and aged/T2D mice.”
Cited by
Functions and mechanisms of microglia/macrophages in neuroinflammation and neurogenesis after stroke
Xiong, X.-Y., Liu, L., & Yang, Q.-W. (2016) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2016.05.001 · Cited by 701
“For instance, agents or endogenous molecules such as execdin-4 (Darsalia et al., 2014), recombinant FAM19A3 (Shao et al.”
BackgroundAthauda, D., & Foltynie, T. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2016.01.013 · Cited by 383
“59 Darsalia, V. et al. (2012) Glucagon-like peptide-1 receptor activation reduces ischaemic brain damage following stroke in type 2 diabetic rats.”
BackgroundShan, Y., Tan, S., Lin, Y., Liao, S., Zhang, B., Chen, X., Wang, J., Deng, Z., Zeng, Q., Zhang, L., et al. (2019) · Journal of Neuroinflammation · doi:10.1186/s12974-019-1638-6 · Cited by 188
Curcumin Protects against Ischemic Stroke by Titrating Microglia/Macrophage Polarization
Liu, Z., Ran, Y., Huang, S., Wen, S., Zhang, W., Liu, X., Ji, Z., Geng, X., Ji, X., Du, H., et al. (2017) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2017.00233 · Cited by 184
“, 2016), and Exendin-4 (Darsalia et al., 2014) have the capacity to promote M2 polarization in microglia.”
Neuroinflammation as a Key Driver of Secondary Neurodegeneration Following Stroke?
Stuckey, S. M., Ong, L. K., Collins‐Praino, L. E., & Turner, R. J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222313101 · Cited by 171
Metadata
- Authors
- Darsalia, V., Hua, S., Larsson, M., Mallard, C., Nathanson, D., Nyström, T., Sjöholm, Å., Johansson, M. E., & Patrone, C.
- Affiliations
- Karolinska Institutet (SE)
- University of Gothenburg (SE)
- Södertälje Sjukhus (SE)
- Corresponding author
- Darsalia, Vladimer
- Patrone, Cesare
- ORCID
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2014-08-07
- Volume
- 9
- Issue
- 8
- Pages
- e103114
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC4125154
- OpenAlex
- W2009256046
- Cited by
- 92
- References
- 41
- Citations by year
- 2026: 3 · 2025: 5 · 2024: 5 · 2023: 4 · 2022: 8 · 2021: 11 · 2020: 7 · 2019: 16 · 2018: 8 · 2017: 12 · 2016: 5 · 2015: 8
- FWCI
- 4.33
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS ONE (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Eli Lilly and Company
- Diabetes Research and Wellness Foundation
- European Foundation for the Study of Diabetes
- AFA Försäkring
- Novo Nordisk
- Vetenskapsrådet
- Konung Gustaf V:s och Drottning Victorias Frimurarestiftelse
- Svenska Läkaresällskapet
- Diabetesfonden (DIA2013-010)
- Topics
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Life Sciences › Neuroscience › Neurology › Neuroprotection in Cerebral Ischemia
- Health Sciences › Medicine › Clinical Neurology › Acute Ischemic Stroke Management
- Keywords
- exendin-4, type 2 diabetes, ischemic stroke, neuroprotection, microglial M2 polarization, neuroinflammation, middle cerebral artery occlusion, GLP-1 receptor agonists, inflammatory cytokines, M1/M2 microglia
- MeSH terms
- Exenatide, Animals, Brain Ischemia, Diabetes Mellitus, Experimental, Diabetes Mellitus, Type 2, Drug Evaluation, Preclinical, Male, Mice, Inbred C57BL, Peptides, Phenotype, Time Factors, Venoms, Biomarkers, Microglia, Neuroprotective Agents, Infarction, Middle Cerebral Artery, Stroke, Gene Expression Profiling
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.